BUR vs NTB

The deterministic health scores paint a concerning picture, with a Piotroski F-Score of just 3/9 indicating weak financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong profitability margins and a low Price/Book ratio, the company faces severe revenue contraction (YoY growth of -73.60%) and deeply negative earnings surprises, with 11 of the last 12 quarters missing or drastically underperforming estimates. While the stock trades below the Graham Number of $10.01, suggesting slight undervaluation, the weak fundamentals, deteriorating growth, and lack of insider support undermine this. The strong_buy analyst consensus appears overly optimistic given the deteriorating operational performance and bearish technical trend.

The deterministic health baseline shows a stable Piotroski F-Score of 4/9, while the stock is fundamentally undervalued, trading below its Graham Number ($60.92) and significantly below its Intrinsic Value ($170.21). The company exhibits exceptional operational efficiency with an ROE of 21.95% and a stellar 25-quarter track record of earnings beats. While technical trends are currently bearish (10/100) and revenue growth is modest, the strong earnings growth (24.4%) and sustainable dividend payout ratio suggest a high-quality value opportunity.